Alvotech and Fuji Pharma Enter into Exclusive Partnership for Development and Commercialization of Biosimilars in Japan

Alvotech and Fuji Pharma (Tokyo Stock Exchange: 4554) today announce that the two companies are entering into an exclusive partnership for the commercialization by Fuji Pharma of Alvotechs biosimilar portfolio in Japan.

Under the partnership, Alvotech will be responsible for development and supply of multiple high value biosimilar assets from its current product pipeline, while Fuji Pharma will be responsible for registration and commercialization of these assets in Japan. Alvotechs biosimilar portfolio includes high value products used in advanced therapies of oncology, ophthalmology and autoimmune disease that generated over $32 billion in global sales in 2017 (Evaluate).

The partnership has been made with a view to establishing a long-term relationship that also gives Fuji Pharma the opportunity to invest in Alvotechs capital structure. The partnership is based on shared values and a joint commitment to drive positive change for patients around the world. In partnering with Fuji Pharma, Alvotech will gain access to Japans fast-growing biosimilars market, forecasted to grow as much as 35% CAGR over the next years. Fuji Pharma, established in 1965, will use its strong local expertise as it goes about commercializing Alvotechs portfolio.

Rasmus Rojkjaer, Alvotechs Chief Executive Officer, said, We are very proud to announce our strategic alliance with Fuji Pharma – a pioneer in the Japanese biosimilars market. We strongly believe that in combining Alvotechs significant manufacturing capacity and high value biosimilars portfolio with Fuji Pharmas deep market experience, we will together be staking a place as leaders in Japans rapidly growing biosimilars market. We are excited to continue delivering on our expanding commitment to bring high quality biosimilars to patients worldwide.

 Stay Updated To Save Money & Time. Join Our Free Newsletter 
. Indepth Analysis & Opinion       . Interviews      . Exclusive Reports  
. Free Digital Magazines      News & updates      . Event Invitations 
                     
& Much More Delivered To Your Inbox For Free.
Submit
We Will Not Spam, Rent, or Sell Your Information.
All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.

 

Fuji Pharmas President and CEO Mr. Eiji Takamasa added, Both Fuji Pharma and Alvotech share the same management philosophy that fuels our excitement to partner with each other. Together we will ensure that patients in Japan will get high quality biosimilars, while reducing the cost burden on the aging Japanese society. Fuji Pharmas strong market reach in Japan, complemented with Alvotechs futuristic portfolio of the expected first-to-launch biosimilar products, will provide the critical synergies for the success of this partnership.

About Alvotech

Alvotech hf. is a privately-owned biopharmaceutical company focused on the development and manufacturing of high quality biosimilars for global markets. We are specialists in biotechnology all working towards a common goal: to be a global leader in the biosimilar space and to deliver high quality cost competitive products and services to our partners and to patients worldwide.

About Fuji Pharma

Fuji Pharma Co., Ltd. is a Tokyo Stock Exchange (TSE) listed, Japan-based pharmaceutical company mainly engaged in the manufacture and sale of prescription based pharmaceutical products. Fuji Pharma focuses on development and commercialization of hormone medicines for obstetrics and gynecology therapies, as well as injectable drugs including radiopharmaceutical products. Fuji Pharma was among the pioneers in Japan to develop and obtain biosimilar approval in Japan for GCSF in 2012.

Alvotech
Halldor Kristmannsson, [email protected]

 Stay Updated To Save Money & Time. Join Our Free Newsletter 
. Indepth Analysis & Opinion       . Interviews      . Exclusive Reports  
. Free Digital Magazines      News & updates      . Event Invitations 
                     
& Much More Delivered To Your Inbox For Free.
Submit
We Will Not Spam, Rent, or Sell Your Information.
All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.

 
Close
Stay Updated To Save Money & Time. Join Our Free Newsletter. 
. Indepth Analysis & Opinion       Interviews          . Exclusive Reports 
. Free Digital Magazines        . News & updates        . Event Invitations
& Much More Delivered To Your Inbox For Free. 
Submit
We Will Not Spam, Rent, or Sell Your Information.
All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.
 
Close